What question did this study set out to answer?

Evaluate the feasibility, infrastructure adaptations, and scalability of utilizing plant-based expression systems for very-large-scale manufacturing of monoclonal antibodies.

March 25, 2017Biotechnology AdvancesOpen Access

Very-large-scale production of antibodies in plants: The biologization of manufacturing

View Full Paper

Ask AI

Bookmark

Authors

JBJohannes F. Buyel RTRichard M. Twyman RFRainer Fischer

Discussion

Member takes

Overview

Technology review demonstrates plant-based platforms can overcome drug supply bottlenecks, indicating a viable pathway for very-large-scale antibody manufacturing.

Key Points

Evaluate the feasibility, infrastructure adaptations, and scalability of utilizing plant-based expression systems for very-large-scale manufacturing of monoclonal antibodies.
Analyzed capacity constraints of conventional fermenter systems against projected market demands for monoclonal antibodies in high-incidence diseases.
Assessed plant-derived bioprocessing platforms, scale-down development models, and operational parallels from the food industry and cell-culture manufacturing.
Traditional bioreactor systems lack the capacity required to support broad monoclonal antibody applications for common, high-prevalence medical conditions.
Plant systems provide an adaptable, high-volume production alternative when combined with specialized downstream processing strategies adapted from industrial food manufacturing.

Cite This Study

Buyel et al. (2017) studied this question.

synapsesocial.com/papers/6a7a17e302ab7a73dd02b7db https://doi.org/10.1016/j.biotechadv.2017.03.011

View Full Paper

Ask AI

Bookmark

March 25, 2017Biotechnology AdvancesOpen Access

Very-large-scale production of antibodies in plants: The biologization of manufacturing

View Full Paper

Ask AI

Bookmark

Authors

JBJohannes F. Buyel RTRichard M. Twyman RFRainer Fischer

Discussion

Member takes

Overview

Technology review demonstrates plant-based platforms can overcome drug supply bottlenecks, indicating a viable pathway for very-large-scale antibody manufacturing.

Key Points

Evaluate the feasibility, infrastructure adaptations, and scalability of utilizing plant-based expression systems for very-large-scale manufacturing of monoclonal antibodies.
Analyzed capacity constraints of conventional fermenter systems against projected market demands for monoclonal antibodies in high-incidence diseases.
Assessed plant-derived bioprocessing platforms, scale-down development models, and operational parallels from the food industry and cell-culture manufacturing.
Traditional bioreactor systems lack the capacity required to support broad monoclonal antibody applications for common, high-prevalence medical conditions.
Plant systems provide an adaptable, high-volume production alternative when combined with specialized downstream processing strategies adapted from industrial food manufacturing.

Cite This Study

Buyel et al. (2017) studied this question.

synapsesocial.com/papers/6a7a17e302ab7a73dd02b7db https://doi.org/10.1016/j.biotechadv.2017.03.011

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark